Is Egrifta (Tesamorelin) Legal in Oregon?

HealthRX.com

Egrifta is an FDA-approved prescription drug in Oregon

Print or save as PDF

Key numbers

  • 1.4 mgEgrifta SV dose, once daily; Egrifta WR is 1.28 mg once daily and the two are not substitutableSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 3 SDSIGF-1 level above which the label says to consider stopping treatment, especially if fat loss is weakSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 25%Tesamorelin patients with injection-site reactions in first 26 weeks, versus 14% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 5%Tesamorelin patients reaching HbA1c 6.5% or higher by week 26 in the trialsSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026

See the public record for Tesamorelin

  • Federal status / FDA-approved prescription drug, first approved November 10, 2010 (BLA 022505) [1]
  • Approved use / Excess abdominal fat in HIV-infected adults with lipodystrophy [3]
  • Current products / Egrifta SV 1.4 mg once daily and Egrifta WR 1.28 mg once daily; the formulations are not substitutable [3][4]
  • Oregon pharmacy law / ORS chapter 689 covers pharmacists, drug outlets and drug sales [2]
  • Compounding / FDA places tesamorelin in no category on its compounding lists [5][6][7]
  • Sport / Prohibited at all times under WADA category S2.2.4 [8]

What the FDA approval covers

Egrifta is indicated for one thing: reducing excess abdominal fat in HIV-infected adults with lipodystrophy. The label adds three limits: long-term cardiovascular safety has not been established, the drug is not indicated for weight loss management because its effect on weight is neutral, and there are no data showing improved adherence to antiretroviral therapy [3].

Tesamorelin is a synthetic analog of human growth hormone-releasing factor, a peptide rather than growth hormone itself. It binds GRF receptors on pituitary somatotroph cells and prompts the pituitary to release the body's own growth hormone, which in turn raises IGF-1 and IGFBP-3 [3].

What Oregon law says about tesamorelin

Oregon's pharmacy statutes are compiled in ORS chapter 689, titled Pharmacists; Drug Outlets; Drug Sales. The chapter covers licensing of pharmacists and drug outlets, labeling and prescription records, and includes a section titled Prohibited practices [2]. None of the section titles refers to tesamorelin [2].

Egrifta itself is a prescription product, not sold over the counter [1].

Questions worth asking

Choose the questions you want to keep

What about compounded tesamorelin?

FDA keeps lists of bulk drug substances for state-licensed pharmacies and for outsourcing facilities. Tesamorelin appears in no category on either list, and it does not appear on FDA's page of bulk substances that may present significant safety risks (content dated April 22, 2026), so the agency has made no category-based statement about compounding it [5][6][7]. Tesamorelin is also not one of the six peptides named in HHS's draft enforcement-discretion policy for compounding, filed October 28, 2026 as Federal Register document 2026-22192 [9][10].

Compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before they are marketed [10]. Tesamorelin is a component of an FDA-approved drug, Egrifta [1].

Is tesamorelin prohibited in sport?

WADA's Prohibited List names tesamorelin in S2.2.4 among growth hormone releasing factors, prohibited at all times, in and out of competition [8]. It stays on the 2027 Prohibited List [11].

What does the label say to watch for?

The Egrifta SV and Egrifta WR labels contraindicate tesamorelin in people with disruption of the hypothalamic-pituitary axis (hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation or head trauma), active malignancy, known hypersensitivity to tesamorelin or its excipients, and pregnancy [3][4].

The label says to monitor IGF-1 and to consider stopping if levels stay high (for example above 3 SDS), particularly when the fat-loss response is not robust, and to evaluate glucose before and during treatment [3]. In the trials, 5% of tesamorelin-treated patients and 1% of placebo patients reached an HbA1c of 6.5% or higher by week 26, a hazard ratio of about 3.3 (95% CI 1.4 to 9.6) [3]. Injection-site reactions occurred in 25% of tesamorelin patients versus 14% on placebo during the first 26 weeks [3].

Is Egrifta (tesamorelin) legal in Oregon?
Egrifta is an FDA-approved prescription drug, not sold over the counter [1]. The section titles of ORS chapter 689, which covers pharmacists, drug outlets and drug sales, name no rule specific to tesamorelin [2].
Is compounded tesamorelin legal in Oregon?
FDA has placed tesamorelin in no category on its lists of bulk substances for state-licensed pharmacies or for outsourcing facilities, and it is not on FDA's page of substances that may present significant safety risks [5][6][7]. Compounded drugs do not go through FDA review before marketing [10].
What is tesamorelin approved to treat?
Reducing excess abdominal fat in HIV-infected adults with lipodystrophy. The label says it is not indicated for weight loss management and that long-term cardiovascular safety has not been established [3].
What dose of Egrifta is approved?
Egrifta SV is 1.4 mg once daily and Egrifta WR is 1.28 mg once daily, both injected subcutaneously into the abdomen. The labels state the two formulations are not substitutable [3][4].
Is tesamorelin banned in sport?
WADA names tesamorelin in S2.2.4 and prohibits it at all times, in and out of competition [8]. It also appears on the 2027 Prohibited List [11].
Show all 11 referencesHide references
Evidence overview for Is Egrifta (Tesamorelin) Legal in Oregon?